16 Acute Myeloid Leukemia Clinical Trials in Tampa, FL (2026)

Q: How do I join a clinical trial in Tampa?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Tampa research site will contact you.

Recruiting Acute Myeloid Leukemia Studies in Tampa

NCT05237258Recruiting

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcome...

Tampa, FLNA2,300 participantsMassachusetts General Hospital

View Study Details

NCT07581002Recruiting

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow (the spongy tissue inside the ...

Tampa, FLPHASE2660 participantsAbbVie

View Study Details

NCT05429632Recruiting

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

This is a multi-center, randomized, double-blinded, placebo controlled trial....

Tampa, FLPHASE3366 participantsPriothera SAS

View Study Details

NCT03802695Recruiting

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transpla...

Tampa, FLPHASE1300 participantsOrca Biosystems, Inc.

View Study Details

NCT02074839Recruiting

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mu...

Tampa, FLPHASE1291 participantsInstitut de Recherches Internationales Servier

View Study Details

NCT06656494Recruiting

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

Evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ICP-248 in combination with azacitidine in patients with acute myelogenous leukemia and Myelodysplastic Syndromes....

Tampa, FLPHASE1266 participantsBeijing InnoCare Pharma Tech Co., Ltd.

View Study Details

NCT04588922Recruiting

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies

SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation grou...

Tampa, FLPHASE1160 participantsSellas Life Sciences Group

View Study Details

NCT06969430Recruiting

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

The primary purpose of Phase 1 is to assess the doses studied under Phase 1 (Dose Escalation) Arm A and identify the recommended dose (RD) for further development (Dose optimization). The primary obj...

Tampa, FLPHASE1154 participantsDebiopharm International SA

View Study Details

NCT06533761Recruiting

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

This is a Phase 1b open-label, multicenter, dose-escalation and dose-optimization study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor effi...

Tampa, FLPHASE1125 participantsStelexis BioSciences

View Study Details

NCT06846606Recruiting

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinica...

Tampa, FLPHASE169 participantsAuron Therapeutics, Inc.

View Study Details

NCT05143996Recruiting

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)...

Tampa, FLPHASE160 participantsCullinan Therapeutics Inc.

View Study Details

NCT06660368Recruiting

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

This multicenter, open-label phase II study combines CLAG-based therapy with or without venetoclax in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) in order to improve measur...

Tampa, FLPHASE252 participantsH. Lee Moffitt Cancer Center and Research Institute

View Study Details

NCT06552416Recruiting

Safety of MT-401-OTS in Patients With Relapsed AML or MDS

This study is a Phase 1 multicenter, open-label study evaluating the safety and efficacy of escalating doses of MT-401-OTS in 2 participant populations: 1) Those with intermediate or high-risk AML per...

Tampa, FLPHASE140 participantsMarker Therapeutics, Inc.

View Study Details

NCT06511882Recruiting

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

The purpose of this research study is to see if people whose Acute myeloid leukemia (AML) is being successfully treated with azacitidine or decitabine in combination with venetoclax can discontinue th...

Tampa, FLPHASE237 participantsH. Lee Moffitt Cancer Center and Research Institute

View Study Details

NCT05024552Recruiting

Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

This study combines vyxeos and gilteritinib in patients with relapsed or refractory FLT3-mutated acute myeloid leukemia. Vyxeos and gilteritinib will be given as induction therapy. Those patients ente...

Tampa, FLPHASE122 participantsH. Lee Moffitt Cancer Center and Research Institute

View Study Details

NCT05558124Recruiting

CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML

The purpose of the study is to determine the safety of combining the drugs gemtuzumab ozogamicin (GO) with CPX-351 in order to treat the disease, as well as to find the maximum tolerated dose level an...

Tampa, FLPHASE118 participantsH. Lee Moffitt Cancer Center and Research Institute

View Study Details

About Acute Myeloid Leukemia Clinical Trials in Tampa

Acute myeloid leukemia (AML) is a fast-growing cancer of the blood and bone marrow characterized by abnormal myeloid cells. It is the most common acute leukemia in adults. Treatment typically includes intensive chemotherapy and may involve stem cell transplant.

There are currently 16 acute myeloid leukemia clinical trials recruiting participants in Tampa, FL. These studies are seeking a combined 4,920 participants. Research is being sponsored by Massachusetts General Hospital, AbbVie, Priothera SAS and 10 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Acute Myeloid Leukemia Clinical Trials in Tampa — FAQ

Are there acute myeloid leukemia clinical trials in Tampa?

Yes, there are 16 acute myeloid leukemia clinical trials currently recruiting in Tampa, FL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Tampa?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Tampa research site will contact you about next steps.

Are clinical trials in Tampa free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Tampa studies also compensate for your time and travel.

What acute myeloid leukemia treatments are being tested?

The 16 active trials in Tampa are testing new therapies including novel drugs, biologics, and treatment approaches for acute myeloid leukemia.

Data updated October 18, 2026 from ClinicalTrials.gov